BG103417A - Condensed pyrimidine bicyclic derivatives - Google Patents

Condensed pyrimidine bicyclic derivatives

Info

Publication number
BG103417A
BG103417A BG103417A BG10341799A BG103417A BG 103417 A BG103417 A BG 103417A BG 103417 A BG103417 A BG 103417A BG 10341799 A BG10341799 A BG 10341799A BG 103417 A BG103417 A BG 103417A
Authority
BG
Bulgaria
Prior art keywords
bicyclic derivatives
condensed pyrimidine
pyrimidine bicyclic
compounds
relates
Prior art date
Application number
BG103417A
Other languages
Bulgarian (bg)
English (en)
Inventor
Lee Arnold
Mikel MOYER
Susan Sobolov-Jaynes
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103417A publication Critical patent/BG103417A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG103417A 1996-11-27 1999-05-20 Condensed pyrimidine bicyclic derivatives BG103417A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3186296P 1996-11-27 1996-11-27
US4184697P 1997-04-09 1997-04-09
PCT/IB1997/001393 WO1998023613A1 (fr) 1996-11-27 1997-11-05 Derives de pyrimidines bicycliques fusionnes

Publications (1)

Publication Number Publication Date
BG103417A true BG103417A (en) 2000-06-30

Family

ID=26707706

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103417A BG103417A (en) 1996-11-27 1999-05-20 Condensed pyrimidine bicyclic derivatives

Country Status (24)

Country Link
US (1) US6413971B1 (fr)
EP (1) EP0946554A1 (fr)
JP (1) JP2000505109A (fr)
KR (1) KR20000057228A (fr)
CN (1) CN1237177A (fr)
AP (1) AP9701146A0 (fr)
AR (1) AR010740A1 (fr)
AU (1) AU4718997A (fr)
BG (1) BG103417A (fr)
BR (1) BR9713552A (fr)
CA (1) CA2272705C (fr)
CO (1) CO4650037A1 (fr)
HN (1) HN1997000146A (fr)
HR (1) HRP970641A2 (fr)
ID (1) ID18958A (fr)
IL (1) IL129825A0 (fr)
IS (1) IS5041A (fr)
MA (1) MA26452A1 (fr)
NO (1) NO992524D0 (fr)
OA (1) OA11051A (fr)
PA (1) PA8442001A1 (fr)
PE (1) PE17299A1 (fr)
TN (1) TNSN97192A1 (fr)
WO (1) WO1998023613A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4275733B2 (ja) * 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジンおよびその製造法
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
EP1005470B1 (fr) 1997-08-22 2007-08-01 AstraZeneca AB Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1226136B1 (fr) 1999-10-19 2004-12-29 Merck & Co., Inc. Inhibiteurs de tyrosine kinases
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1676845B1 (fr) 1999-11-05 2008-06-11 AstraZeneca AB Nouveaux dérivés de type quinazoline
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
ES2245955T3 (es) 1999-12-21 2006-02-01 Sugen, Inc. 7-aza-indolin-2-onas 4-sustituidas y su utilizacion como inhibidores de proteina-quinasa.
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2223827T3 (es) 2000-06-06 2005-03-01 Pfizer Products Inc. Derivados de tiofeno utiles como agentes anticancerigenos.
CN100351253C (zh) 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
WO2002032861A2 (fr) 2000-10-17 2002-04-25 Merck & Co., Inc. Sels oralement actifs a activite tyrosine kinase
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
ES2372028T3 (es) 2000-10-23 2012-01-13 Glaxosmithkline Llc Nuevo compuesto de 8h-pirido[2,3-d]pirimidin-7-ona trisustituida para el tratamiento de enfermedades mediadas por la csbp/p38 quinasa.
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003000194A2 (fr) 2001-06-21 2003-01-03 Pfizer Inc. Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1471910A2 (fr) * 2002-01-17 2004-11-03 Neurogen Corporation Analogues de quinazoline-4-ylamine substitues comme modulateurs de receptors de la capsaicin
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
KR20050086784A (ko) 2002-11-26 2005-08-30 화이자 프로덕츠 인크. 이식 거부반응의 치료 방법
US7432275B2 (en) * 2002-12-13 2008-10-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
AU2004270740A1 (en) * 2003-09-09 2005-03-17 Neurogen Corporation 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
JP2007511596A (ja) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
CN1890234A (zh) 2003-12-23 2007-01-03 辉瑞大药厂 新颖的喹啉衍生物
CA2566160C (fr) 2004-05-27 2011-01-18 Pfizer Products Inc. Derives pyrrolopyrimidiniques convenant au traitement du cancer
ZA200610669B (en) * 2004-06-02 2008-06-25 Takeda Pharmaceutical Fused heterocyclic compound
WO2005118588A1 (fr) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Composé heterocyclique fusionné
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
RU2467007C2 (ru) 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
EP2345652A1 (fr) 2005-12-21 2011-07-20 Abbott Laboratories Composées antivirales
TW200738707A (en) * 2005-12-21 2007-10-16 Abbott Lab Anti-viral compounds
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CA2672737A1 (fr) * 2006-12-20 2008-11-06 Abbott Laboratories Composes antiviraux
EP2119707B1 (fr) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN104311563B (zh) * 2007-11-28 2016-12-07 达那-法伯癌症研究所 Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
CA2733359C (fr) 2008-08-20 2014-08-05 Pfizer Inc. Composes pyrrolo[2,3-d]pyrimidines
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9139590B2 (en) 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
WO2012166899A2 (fr) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
WO2013174735A1 (fr) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Benzothienopyrimidines substituées
AP3902A (en) * 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2900671A1 (fr) 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Indazol-pyrrolopyrimidines substituées utiles dans le traitement de maladies hyperprolifératives
JP2015531361A (ja) 2012-09-26 2015-11-02 バイエル・ファルマ・アクティエンゲゼルシャフト 過剰増殖性疾患の治療に有用な置換インダゾール−ピロロピリミジン
CA2887539C (fr) 2012-11-29 2021-10-26 Merck Patent Gmbh Derives carboxamide d'azaquinazoline
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016193860A1 (fr) 2015-06-04 2016-12-08 Pfizer Inc. Formes galéniques solides de palbociclib
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
KR102236605B1 (ko) 2016-08-15 2021-04-05 화이자 인코포레이티드 피리도피리미딘온 cdk2/4/6 억제제
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
JP2023519605A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
WO2021198955A1 (fr) 2020-03-31 2021-10-07 Nuevolution A/S Composés actifs vis-à-vis des récepteurs nucléaires

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU686843B2 (en) * 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
JPH089637A (ja) * 1994-06-20 1996-01-12 Shindengen Electric Mfg Co Ltd Ｆｅｔによる出力スイッチの駆動回路
DE69609602T2 (de) * 1995-04-03 2001-04-12 Novartis Ag Pyrazolderivate und verfahren zu deren herstellung
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
JPH08329674A (ja) * 1995-06-02 1996-12-13 Hitachi Ltd 半導体装置
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
AU5692298A (en) * 1996-11-26 1998-06-22 American Cyanamid Company Biaryl-pyridoquinazolinone derivatives as anti-cancer agents

Also Published As

Publication number Publication date
TNSN97192A1 (fr) 2005-03-15
AP9701146A0 (en) 1998-01-31
IS5041A (is) 1999-04-30
PA8442001A1 (es) 2000-05-24
ID18958A (id) 1998-05-28
JP2000505109A (ja) 2000-04-25
OA11051A (en) 2003-03-07
US6413971B1 (en) 2002-07-02
AU4718997A (en) 1998-06-22
PE17299A1 (es) 1999-02-19
NO992524L (no) 1999-05-26
CN1237177A (zh) 1999-12-01
CO4650037A1 (es) 1998-09-03
NO992524D0 (no) 1999-05-26
IL129825A0 (en) 2000-02-29
US20020045630A1 (en) 2002-04-18
EP0946554A1 (fr) 1999-10-06
HRP970641A2 (en) 1998-10-31
HN1997000146A (es) 1998-02-26
CA2272705C (fr) 2003-03-18
KR20000057228A (ko) 2000-09-15
CA2272705A1 (fr) 1998-06-04
BR9713552A (pt) 2000-01-25
MA26452A1 (fr) 2004-12-20
WO1998023613A1 (fr) 1998-06-04
AR010740A1 (es) 2000-07-12

Similar Documents

Publication Publication Date Title
BG103417A (en) Condensed pyrimidine bicyclic derivatives
CA2258548A1 (fr) Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BG103947A (en) Derivatives of 9-oxymerythromycin
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
SE9702001D0 (sv) Novel compounds
MY119181A (en) Aryl pyrimidine derivatives
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
HUT71130A (en) Condensed indole derivatives of protein kinase c inhibitor activity, process for preparing them and pharmaceutical compositions containing them
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
BG101110A (en) Substituted pyrimidine compounds and their application
WO1997030677A3 (fr) Pentafluorobenzenesulfonamides et analogues
AP9701041A0 (en) Pyridylpyrrole compounds.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
AU1428801A (en) Novel (1,2,3)-triazolo(4,5-D)pyrimidine compounds
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
YU64400A (sh) Aril fuzirana azapoliciklična jedinjenja
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
YU46302A (sh) Supstituisani piroli
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena
AU579196B2 (en) 4-Oxo-piridol(2,3-d)pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof